Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Sarah Blagden

Contact information

Email
sarah.blagden@oncology.ox.ac.uk

Sarah Blagden

Professor of Experimental Oncology

Lead for Oxford Cancer Trials Office (OCTO)

Recent publications

Hedgehog Inhibitor and Paclitaxel: A Phase I Trial of the Oral Hedgehog inhibitor Taladegib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumours.

Glasspool R. et al, (2026), Invest New Drugs

The circulating proteome and cancer risk: a systematic literature review and meta-analysis of 26 prospective studies with genetic validation.

Dillman A. et al, (2026), EBioMedicine, 124

Housing and health inequalities: why is housing on the periphery of health and welfare policy?

Harding A. et al, (2026), Frontiers in Environmental Health, 5

Clinical Impact of Next-Generation Sequencing-Guided Targeted Therapies in Advanced Cancer: A Systematic Review and Meta-Analysis.

Kazmi F. et al, (2025), Clin Oncol (R Coll Radiol), 48

A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.

Sooi K. et al, (2025), Br J Cancer, 133, 896 - 908

More publications